Chordoma clinical trials
9 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- Pembrolizumab and Pemetrexed for Progressive Chordoma
- Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
- A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis
- Children and Adults With Chordoma
- Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
- Clinical Genetics Branch Eligibility Screening Survey
- Long-Term Longitudinal QoL in Patients Undergoing EEA
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Chordoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.